Molecular newborn screening is being pushed as the next step for hemoglobinopathies
Newborn screening for sickle cell disease has long been one of pediatrics’ most consequential public health programs, but the current model leaves too much room for uneven detection and uneven follow-up. A Special Communication in JAMA Health Forum argues that the field has reached a point where universal molecular genetic testing should replace protein-based approaches for hemoglobinopathies, not only to improve diagnostic precision but also to reduce the geographic and insurance-based disparities that still shape who gets confirmatory testing and who does not.
The case for change begins with the burden of disease. Hemoglobin disorders affect more than 500,000 infants born each year worldwide, and newborn screening for sickle cell disease, first introduced in the 1970s and later added to the Recommended Uniform Screening Panel in 2006, has already changed childhood survival for the better. Yet sickle cell disease is only part of the picture. Existing screening programs also detect other hemoglobinopathies, and the clinical meaning of those findings can vary widely depending on genotype, test method, and access to follow-up evaluation.
A single positive screen can represent several different biological realities. When the initial assay is protein based, newborns may be labeled through a pathway that does not fully define the underlying genotype, and that gap can matter because the expression of hemoglobin disorders is shaped by specific variants, not just by the presence of an abnormal screen. In practice, this means that two infants with similar screening results may face very different prognoses, yet current state-by-state screening systems do not always provide the same level of clarity or confirmation.
State variation leaves confirmation and reporting inconsistent
The article describes a fragmented screening environment in which individual states administer newborn screening programs with inconsistent choices for the primary test, the reporting process, and the follow-up of abnormal results. Genetic confirmation is not uniformly available, and that inconsistency creates a chain reaction: some infants receive prompt, definitive diagnosis, while others remain in limbo after an abnormal screen. The result is not just administrative variation. It is a public health system that can sort infants by where they are born and what insurance coverage they have.
That inequity has direct clinical consequences. A newborn identified through protein-based screening alone may carry a genotype that changes the natural history of the disease, but without molecular confirmation, clinicians can be forced to act on incomplete information. Earlier referral to definitive care depends on knowing what the screen actually means. Delays in that process can weaken the purpose of universal screening in the first place.
Molecular testing offers specificity the current system cannot match
The proposed alternative is targeted genetic testing of the hemoglobin genes HBA1, HBA2, and HBB. These genes are especially well suited to molecular newborn screening because hemoglobinopathies have an extensive variant database that can be used to predict pathogenicity. In other words, the biology of the disorders makes them unusually compatible with genomic screening: the causal variants are well characterized, and the testing can provide diagnostic specificity without relying on repeated secondary assays.
That specificity matters because the current model can force multiple downstream tests to resolve a result that could have been clarified earlier. Molecular screening could compress that process into a single platform, with fewer handoffs and fewer opportunities for results to stall in the system. For families, the practical effect would be fewer ambiguous calls and faster access to definitive counseling and care.
There is also a surveillance advantage. Standardizing screening with diagnostic specificity would improve public health data quality, which in turn affects resource allocation. Health systems depend on accurate counts, clear case definitions, and reliable genotype data when deciding where to send personnel, how to structure specialty referral networks, and how to budget for long-term disease management. A screening program that identifies the right infants more consistently can also identify the size of the problem more accurately.
Technical barriers remain, but they are described as manageable
The argument for universal molecular newborn screening does not ignore the operational burden. Bringing new technology online would require workflow changes, laboratory training, and likely higher upfront cost. Genetic data protection also enters the discussion, because a molecular platform introduces questions about how sensitive information is stored, transferred, and safeguarded within public health systems.
Those barriers are real. They are also presented as solvable.
High-throughput methods could reduce some of the technical strain, especially if molecular hemoglobinopathy screening is consolidated with other genetic tests already used in newborn programs. Multiplexing offers a path to efficiency: one platform, several disorders, and a more streamlined laboratory process. In that model, the cost and complexity of molecular testing may be softened by broader deployment across conditions that already require genetic screening at birth.
The communication does not frame molecular testing as a narrow laboratory upgrade. It treats the issue as a redesign of the screening system itself. A test with diagnostic specificity changes what follows next: who gets called back, how fast referral happens, and whether confirmation depends on where a child was born. For disorders in which early identification is meant to prevent avoidable harm, the quality of the first screen shapes the entire care pathway.
A shift toward universal molecular testing
The authors argue that universal adoption of molecular testing can overcome the shortcomings of state-by-state variation, especially the uneven access to confirmatory evaluation. The proposal is built on a simple clinical premise: if the screening tool can identify the genotype with greater certainty at the outset, then the program can reduce ambiguity, improve equity, and support timely treatment decisions.
This is where the public health case becomes strongest. Universal newborn screening already exists to prevent delayed diagnosis in infants with conditions that worsen quickly if missed. Hemoglobinopathies fit that model. By shifting to molecular testing, screening could become less dependent on local infrastructure and less vulnerable to gaps in confirmatory access. The system would be built around the disease biology rather than around the limitations of a protein assay.
The article closes with a clear position: the time has come for a paradigm shift in newborn screening for hemoglobinopathies through universal molecular genetic testing. The remaining questions are operational rather than conceptual—how quickly programs can adopt the platform, how states will standardize reporting, and how genetic data protections will be implemented without slowing the transition.